Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 3/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | ITPR3 | Q14573 | 7/20 | 0.32 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.32 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.32 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431004 | 0.86 | INPP5A (0.42) | INPP5ASMPD1S1PR4S1PR1S1PR3 | |
| SCHEMBL10241873 | 0.80 | INPP5A (0.43) | INPP5ASMPD1S1PR4S1PR1S1PR3 | |
| SCHEMBL3430655 | 0.76 | — | — | |
| SCHEMBL2238965 | 0.76 | — | — | |
| SCHEMBL2149479 | 0.71 | INPP5A (0.52) | INPP5ASMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL2238021 | 0.71 | — | — | |
| SCHEMBL6026425 | 0.70 | INPP5A (0.41) | INPP5AS1PR4S1PR1S1PR3ANPEP | |
| SCHEMBL3431189 | 0.70 | EPHX2 (0.44) | — | |
| SCHEMBL18501082 | 0.69 | S1PR4 (0.37) | S1PR4S1PR1S1PR3ANPEPERAP2 | |
| SCHEMBL15105636 | 0.69 | INPP5A (0.50) | INPP5ASMPD1ITPR3ITPR2ITPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | INPP5A 1058/4885SMPD1 1752/4885S1PR4 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.